LONDON (Reuters) – Novo Nordisk’s obesity drug Wegovy reduced kidney-related events by 22% in overweight and obese individuals. The Danish drugmaker disclosed this analysis on Saturday.
Results from a large study, previously disclosed by Novo, were presented at the European Renal Congress in Stockholm. The analysis showcased significant findings.
“By addressing key markers of kidney health, semaglutide…may contribute to a significant reduction in the risk of kidney-related complications, including chronic kidney disease and end-stage renal disease,” said Professor Helen M. Colhoun of the University of Edinburgh and lead study author.
A Novo spokesperson said in a statement to Reuters that the new analysis “demonstrates for the first time the benefits of semaglutide 2.4 mg in improving kidney function in people with cardiovascular disease and overweight or obesity, without diabetes, a high-risk population with increased need for kidney protection.”
The study, released in March, demonstrated that Novo’s diabetes drug Ozempic could delay chronic kidney disease progression in diabetic patients. Ozempic and Wegovy share the active ingredient semaglutide.
Furthermore, the analysis revealed that Wegovy users exhibited improved kidney health markers over time.
Moreover, the findings suggest that Wegovy may offer additional benefits beyond weight management, particularly for individuals at risk of developing kidney-related issues.
read more
image source
